These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 1725540

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers.
    Winther K, Gleerup G, Hedner T.
    J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S41-4. PubMed ID: 1725542
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients.
    van Harten J, van Brummelen P, Danhof M, Quekel RP, Breimer DD.
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):624-9. PubMed ID: 2471001
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Nisoldipine (BAY K 5552), a new calcium antagonist. Antihypertensive effect in conscious, unrestrained renal hypertensive dogs.
    Knorr A.
    Arch Int Pharmacodyn Ther; 1982 Nov; 260(1):141-50. PubMed ID: 7165419
    [Abstract] [Full Text] [Related]

  • 29. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil.
    Rostagno C, Abbate R, Gensini GF, Coppo M, Prisco D, Boddi M, Neri Serneri GG.
    Thromb Res; 1991 Aug 15; 63(4):457-62. PubMed ID: 1754998
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.
    Hilleman DE, Mohiuddin SM, Lucas BD, Shinn B, Elsasser GN.
    Clin Ther; 1993 Aug 15; 15(6):1002-10. PubMed ID: 8111798
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects.
    Leonetti G, Cuspidi C, Sampieri L, Terzoli L, Zanchetti A.
    J Cardiovasc Pharmacol; 1982 Aug 15; 4 Suppl 3():S319-24. PubMed ID: 6184561
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparative hemodynamic dose-response effects of five slow calcium channel-blocking agents in coronary artery disease.
    Silke B, Frais MA, Midtbo KA, Verma SP, Sharma S, Reynolds G, Jackson N, Taylor SH.
    Clin Pharmacol Ther; 1987 Oct 15; 42(4):381-7. PubMed ID: 2959425
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.